P700: TREATMENT-FREE REMISSION (TFR) AFTER DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR): FINAL 5-YEAR RESULTS OF DASFREE
N. P. Shah,
V. García-Gutiérrez,
A. Jiménez-Velasco,
S. Saussele,
D. Rea,
F.-X. Mahon,
M. Y. Levy,
M. T. Gómez-Casares,
M. J. Mauro,
O. Sy,
P. Martin-Regueira,
J. H. Lipton
Affiliations
N. P. Shah
1 UCSF School of Medicine, San Francisco, United States of America
V. García-Gutiérrez
2 Servicio Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid
A. Jiménez-Velasco
3 Hospital Universitario Carlos Haya, Malaga, Spain
S. Saussele
4 Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
D. Rea
5 Hôpital Saint-Louis, Paris
F.-X. Mahon
6 Institut Bergonié Cancer Center, Université Bordeaux, Bordeaux, France
M. Y. Levy
7 Baylor Charles A. Sammons Cancer Center, Dallas, United States of America
M. T. Gómez-Casares
8 Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
M. J. Mauro
9 Memorial Sloan Kettering Cancer Center, New York
O. Sy
10 Bristol Myers Squibb, Princeton, United States of America
P. Martin-Regueira
10 Bristol Myers Squibb, Princeton, United States of America
J. H. Lipton
11 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
